Endocrine Unit, First Propaedeutic Department of Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Pathology, G. Gennimatas, Athens General Hospital, 154 Messogion Ave., BLDG#1, 115 27, Athens, Greece.
Hormones (Athens). 2021 Jun;20(2):287-291. doi: 10.1007/s42000-020-00269-9. Epub 2021 Jan 16.
The World Health Organization (WHO) classifications of tumors offer invaluable support in the diagnosis of tumors, with every new edition including novel information and diagnostic updates. The new 2017 WHO Classification of Tumors of Endocrine Organs, 4th edition, includes innovations in both terminology and diagnostic guidelines for pituitary adenomas, along with new entities, molecular information, and novel treatment modalities. The recommended reporting system of pituitary adenomas is based on morphology and assessment of the hormonal content by immunohistochemistry. Electron microscopy and immunohistochemistry for Ki-67 and p53 and transcription factors, while presenting additional information, are not recommended for routine diagnosis. Other markers may also yield information of prognostic and predictive significance. In sum, the 2017 WHO classification provides pathologists and clinicians with new and comprehensive information of great use for the diagnosis and treatment of pituitary tumors.
世界卫生组织(WHO)的肿瘤分类为肿瘤诊断提供了宝贵的支持,每一个新版本都包含新的信息和诊断更新。新的 2017 年版《世界卫生组织内分泌器官肿瘤分类》包括了在垂体腺瘤的术语和诊断指南方面的创新,以及新的实体、分子信息和新的治疗方式。推荐的垂体腺瘤报告系统基于形态学和免疫组织化学评估激素含量。电子显微镜和 Ki-67、p53 和转录因子的免疫组织化学虽然提供了额外的信息,但不推荐用于常规诊断。其他标志物也可能提供具有预后和预测意义的信息。总之,2017 年版 WHO 分类为病理学家和临床医生提供了新的、全面的信息,对垂体肿瘤的诊断和治疗非常有用。